N4 Pharma Plc

Home

Contact us

Updates

Nuvec® Home

siRNA

Viral vectors

Oral

Vaccines

Our business

Leadership team

Nanogenics

About Us

LipTide®

Partnership opportunities

Investors Home

Regulatory news

AIM Rule 26

Investors

Open Sans

Watch the discussion with Nigel Theobald, CEO of N4 Pharma, as he delves into the Company's recent Collaboration Agreement with SRI International Inc.

0.58 -  2.27: What is the main focus of N4 Pharma for 2024?

2.28 - 3.46: What is Nuvec® and the FOX Three Molecular Guidance System (MGS)?

3.47 -  4.51: What is the significance of combining Nuvec® with SRI's FOX Three Molecular Guidance System (MGS) and does this enhance N4's approach to drug delivery?

4.52 - 5.40: How will the collaboration with SRI lead to more potential partnerships for N4 Pharma?

5.51 - 6.37: How will the collaboration align with N4 Pharma's broader strategic goals and how does it impact the progress of other initiatives?

6.38 - 7.38: What are the expected outcomes or milestones that N4 Pharma aims to achieve through this collaboration?

7.39 - 8.17: Why should investors be excited about this collaboration with SRI?

8.18 - 8.45: What are the funding details for the collaboration?

8.46 - 9.47: How will the collaboration be structured in terms of research direction and control, and when can investors expect to hear updates?

Read the full SRI Collaboration announcement released on the 25th of April here.

Investors are invited to submit any additional questions via N4 Pharma’s investor hub via the 'Ask a question' button. The management team will endeavour to respond as soon as they can.